Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany

Epidemiol Infect. 2022 Nov 8:150:e204. doi: 10.1017/S0950268822001182.

Abstract

This study assessed the incidence rate of all-cause pneumonia (ACP) and invasive pneumococcal disease (IPD) and associated medical costs among individuals aged ≥16 in the German InGef database from 2016 to 2019. Incidence rate was expressed as the number of episodes per 100 000 person-years (PY). Healthcare resource utilisation was investigated by age group and by risk group (healthy, at-risk, high-risk). Direct medical costs per ACP/IPD episode were estimated as the total costs of all inpatient and outpatient visits. The overall incidence rate of ACP was 1345 (95% CI 1339-1352) and 8.25 (95% CI 7.76-8.77) per 100 000 PY for IPD. For both ACP and IPD, incidence rates increased with age and were higher in the high-risk and at-risk groups, in comparison to the healthy group. ACP inpatient admission rate increased with age but remained steady across age-groups for IPD. The mean direct medical costs per episode were €8075 (95% CI 7121-9028) for IPD and €1454 (95% CI 1426-1482) for ACP. The aggregate direct medical costs for IPD and ACP episodes were estimated to be €8.5 million and €248.9 million respectively. The clinical and economic burden of IPD and ACP among German adults is substantial regardless of age.

Keywords: All-cause pneumonia; Germany; claims data; healthcare resource utilisation; invasive pneumococcal disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Costs and Cost Analysis
  • Humans
  • Incidence
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Vaccines
  • Pneumonia* / complications
  • Risk Factors

Substances

  • Pneumococcal Vaccines